Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Andrew W. Roberts Ranjana H. Advani |
| Publication date | May 5, 2015 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |